ALBT - Avalon GloboCare Corp.

0.867
-0.110   -12.710%

Share volume: 988,065
Last Updated: 03-05-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.04%

PREVIOUS CLOSE
CHG
CHG%
$0.98
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
31%
Profitability 35%
Dept financing 43%
Liquidity 5%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-15.83%
1 Month
36.43%
3 Months
-37.17%
6 Months
-63.18%
1 Year
-92.05%
2 Year
118.55%
Key data
Stock price
$0.87
P/E Ratio 
0.00
DAY RANGE
$0.84 - $1.04
EPS 
-$9.53
52 WEEK RANGE
$0.42 - $7.89
52 WEEK CHANGE
-$88.01
MARKET CAP 
9.685 M
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-30-2025
BETA 
-1.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$45,017,517
AVERAGE 30 VOLUME 
$17,318,769
Company detail
CEO: David K. Jin
Region: US
Website: http://www.avalon-globocare.com/
Employees: 5
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Avalon GloboCare Corp. owns and operates commercial real estate properties in the United States and the People's Republic of China. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia. It is also developing RNA-based FASH-CARTM cell therapy platform.

Recent news